Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models
Pharmaceuticals · 2026-07-25 · 19 (8) · 1163
DOI: 10.3390/ph19081163 ↗At a glance
Journal article in Pharmaceuticals, published online on 2026-07-25. Written by Weili Zhang and 5 co-authors. Institution: Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen U…. 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Basic and Applied Basic Research Foundation of Guangdong Province, the Beijing Xisike Clinical Oncology Research Foundation.
Abstract (original language)
Background/Objectives: Sacituzumab govitecan (SG, IMMU-132) is a TROP2-directed antibody–drug conjugate carrying SN-38. Patients with colorectal liver metastasis (CRLM) still have limited treatment options after first-line systemic therapy, and the preclinical pharmacological value of TROP2-directed SN-38 delivery in CRLM remains insufficiently defined.
Methods
Public single-cell RNA-sequencing data were reanalyzed to explore the distribution of TACSTD2/TROP2-positive epithelial-associated cells in adjacent normal tissues, primary colorectal cancer, and CRLM. The prognostic relevance of TACSTD2 was evaluated using the Kaplan–Meier Plotter database. TROP2-knockdown and TROP2-overexpressing colorectal cancer models were used to assess IMMU-132 response in vitro and in vivo. Pharmacological antitumor activity was further evaluated using subcutaneous xenografts, syngeneic intrasplenic liver metastasis models, and CRLM patient-derived organoids (PDOs). Transcriptomic profiling and γ-H2AX immunofluorescence were used to explore treatment-associated molecular changes.
Results
At the patient/sample level, TACSTD2/TROP2-positive epithelial-associated cells showed numerically higher proportions in primary colorectal tumors and liver metastases than in adjacent normal tissues, and high TACSTD2 expression was associated with inferior overall survival in a public survival database. TROP2 knockdown attenuated IMMU-132-induced growth inhibition, apoptosis, and suppression of colony formation. In vivo, IMMU-132 suppressed colorectal tumor growth and reduced liver metastatic burden, with more evident activity in human TROP2-overexpressing models. In a limited exploratory CRLM PDO cohort established after first-line therapy, liver metastasis-derived PDOs showed lower normalized AUC values than primary tumor-derived PDOs. Transcriptomic analysis and representative γ-H2AX immunofluorescence suggested that IMMU-132 treatment was associated with changes in adhesion/cytoskeletal-related pathways, Wnt/cancer-associated transcriptional programs, and DNA damage-associated signals.
Conclusions
These in vitro, in vivo, and PDO-based findings support further preclinical pharmacological evaluation of TROP2-directed SN-38 delivery by IMMU-132 in biomarker-annotated CRLM models, particularly in the post-first-line systemic therapy setting.
Subjects
Author keywords
Authors and institutions
- Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Chi…
ORCID profiles: Weili Zhang, Jianhong Peng
Funding
- the Basic and Applied Basic Research Foundation of Guangdong Province
- the Beijing Xisike Clinical Oncology Research Foundation
Cite
APA
Zhang, W., Wang, R., Situ, Y., Wang, W., Peng, J., & Lu, Z. (2026). Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models. Pharmaceuticals, 19(8), 1163. https://doi.org/10.3390/ph19081163
Vancouver
Zhang W, Wang R, Situ Y, Wang W, Peng J, Lu Z. Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models. Pharmaceuticals. 2026;19(8):1163. doi:10.3390/ph19081163
BibTeX
@article{Zhang2026,
author = {Zhang, Weili and Wang, Ruowei and Situ, Yingting and Wang, Weifeng and Peng, Jianhong and Lu, Zhenhai},
title = {Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1163},
doi = {10.3390/ph19081163}
}
EUVIMED